產(chǎn)品名稱 |
CEM/C1 |
商品貨號 |
B164226 |
Organism |
Homo sapiens, human |
Tissue |
peripheral blood |
Cell Type |
T lymphoblast |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
acute lymphoblastic leukemia |
Age |
4 years |
Gender |
Female |
Ethnicity |
Caucasian |
Storage Conditions |
liquid nitrogen vapor phase |
Images |
|
Derivation |
CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). The cell line was selected and subcloned in 1991 for resistance to CPT.
|
Clinical Data |
4 years Caucasian female |
Comments |
This cell line exhibits cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT.
CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells.
CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity.
Resistance to CPT is stable for up to six months. |
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
Subculturing |
Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 1- 2 x 105 viable cells/mL. Maintain cultures at cell concentrations between 1 x 105 and 2 x 106 viable cells/mL.
Medium Renewal: 2 to 3 times a week.
|
Cryopreservation |
culture medium 95%; DMSO, 5% |
Culture Conditions |
Temperature: 37°C |
Population Doubling Time |
26 hrs |
Name of Depositor |
WG Harker |
Deposited As |
Homo sapiens |
Year of Origin |
1991 |
References |
Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731
Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333
|